Angeles Therapeutics

Executive Summary

Angeles Therapeutics is a private, next-generation cell therapy company based in Los Angeles, California, founded in 2020. The company is developing novel chimeric antigen receptor T cell (CAR-T) and NK cell (CAR-NK) platforms, claiming one of the world's largest portfolios of these assets. While the company has not disclosed its specific pipeline or development stage, its focus on both autologous and allogeneic cell therapies positions it within a highly competitive and rapidly evolving field. The lack of publicly available funding, clinical trial data, or regulatory milestones makes it difficult to assess progress, but the broad portfolio suggests an ambition to target multiple hematologic and solid tumor indications. For investors, the company represents an early-stage, high-risk opportunity with potential upside if its platforms demonstrate differentiation in efficacy, safety, or manufacturing scalability. Near-term visibility is limited, and the company's ability to execute on its vision will depend on securing partnerships or additional financing to advance lead candidates toward the clinic.

Upcoming Catalysts (preview)

• Q3 2026Lead CAR-T Asset IND Filing40% success
• Q4 2026Strategic Partnership or Licensing Deal35% success
• H2 2026Preclinical Data Presentation at Major Conference50% success